 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||
18 September 2007 | Volume 147 Issue 6
Background: As newer oral diabetes agents continue to emerge on the market, comparative evidence is urgently required to guide appropriate therapy.
Purpose: To summarize the English-language literature on the benefits and harms of oral agents (second-generation sulfonylureas, biguanides, thiazolidinediones, meglitinides, and
Data Sources: The MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases were searched from inception through January 2006 for original articles and through November 2005 for systematic reviews. Unpublished U.S. Food and Drug Administration and industry data were also searched.
Study Selection: 216 controlled trials and cohort studies and 2 systematic reviews that addressed benefits and harms of oral diabetes drug classes available in the United States were identified.
Data Extraction: Using standardized protocols, 2 reviewers serially abstracted data for each article.
Data Synthesis: Evidence from clinical trials was inconclusive on major clinical end points, such as cardiovascular mortality. Therefore, the review was limited mainly to studies of intermediate end points. Most oral agents (thiazolidinediones, metformin, and repaglinide) improved glycemic control to the same degree as sulfonylureas (absolute decrease in hemoglobin A1c level of about 1 percentage point. Nateglinide and
Limitations: Data on major clinical end points were limited. Studies inconsistently reported adverse events other than hypoglycemia, and definitions of adverse events varied across studies. Some harms not assessed in trials or observational studies may have been overlooked.
Conclusions: Compared with newer, more expensive agents (thiazolidinediones,
Author and Article Information
From Johns Hopkins University School of Medicine, Johns Hopkins Bloomberg School of Public Health, and Evidence-based Practice Center and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, Maryland, and Washington University School of Medicine, St. Louis, Missouri.
Disclaimer: The authors of this article are responsible for its contents, including any clinical or treatment recommendations. No statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality or of the U.S. Department of Health and Human Services.
Acknowledgments: The authors thank Steven Fox for his help as the Task Order Officer.
Grant Support: This article is based on research conducted by The Johns Hopkins Evidence-based Practice Center under contract number 290-02-0018 with the Agency for Healthcare Research and Quality, Rockville, Maryland. Dr. Brancati was supported by a mid-career investigator award for patient-oriented research in diabetes from the National Institute of Diabetes and Digestive and Kidney Disorders, Bethesda, Maryland (5 K24 DK062222-05).
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Shari Bolen, MD, MPH, Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, 2024 East Monument Street, Suite 2-600, Room 2-615, Baltimore, MD 21205; e-mail, sgolden4{at}jhmi.edu.
Current Author Addresses: Drs. Bolen, Yeh, Selvin, and Brancati: Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, 2024 East Monument Street, Suite 2-600, Baltimore, MD 21205.
Ms. L. Wilson, Ms. R. Wilson, and Drs. Wiley and Bass: Johns Hopkins University, 1830 East Monument Street, Eighth Floor, Baltimore, MD 21287.
Dr. Feldman: Johns Hopkins University, Jefferson Building, 600 North Wolfe Street, Room 242, Baltimore, MD 21287.
Dr. Vassy: University of Pennsylvania Health System, 3400 Spruce Street, Philadelphia, PA 19104.
Dr. Marinopoulos: University Health Services, Johns Hopkins University, 401 North Caroline Street, Baltimore, MD 21231. REVIEW
Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus
-glucosidase inhibitors) in the treatment of adults with type 2 diabetes mellitus. -glucosidase inhibitors may have slightly weaker effects, on the basis of indirect comparisons of placebo-controlled trials. Thiazolidinediones were the only class that had a beneficial effect on high-density lipoprotein cholesterol levels (mean relative increase, 0.08 to 0.13 mmol/L [3 to 5 mg/dL]) but a harmful effect on low-density lipoprotein (LDL) cholesterol levels (mean relative increase, 0.26 mmol/L [10 mg/dL]) compared with other oral agents. Metformin decreased LDL cholesterol levels by about 0.26 mmol/L (10 mg/dL), whereas other oral agents had no obvious effects on LDL cholesterol levels. Most agents other than metformin increased body weight by 1 to 5 kg. Sulfonylureas and repaglinide were associated with greater risk for hypoglycemia, thiazolidinediones with greater risk for heart failure, and metformin with greater risk for gastrointestinal problems compared with other oral agents. Lactic acidosis was no more common in metformin recipients without comorbid conditions than in recipients of other oral diabetes agents. -glucosidase inhibitors, and meglitinides), older agents (second-generation sulfonylureas and metformin) have similar or superior effects on glycemic control, lipids, and other intermediate end points. Large, long-term comparative studies are needed to determine the comparative effects of oral diabetes agents on hard clinical end points.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Hemmingsen, S. S Lund, J. Wetterslev, and A. Vaag Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes Eur. J. Endocrinol., July 1, 2009; 161(1): 1 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Montori and M. Fernandez-Balsells Glycemic Control in Type 2 Diabetes: Time for an Evidence-Based About-Face? Ann Intern Med, June 2, 2009; 150(11): 803 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. St. Onge, S. A. Miller, and J. R. Taylor Novel Approaches to the Treatment of Type 2 Diabetes Journal of Pharmacy Practice, June 1, 2009; 22(3): 320 - 332. [Abstract] [PDF]
|
|
|
|
 |
|
 G. M. Hall and G. Nicholson Current Therapeutic Drugs for Type 2 Diabetes, Still Useful After 50 Years? Anesth. Analg., June 1, 2009; 108(6): 1727 - 1730. [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Cryer, L. Axelrod, A. B. Grossman, S. R. Heller, V. M. Montori, E. R. Seaquist, and F. J. Service Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., March 1, 2009; 94(3): 709 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Thomas, M. Tadayyon, and M. Mark Chronic Treatment with the Dipeptidyl Peptidase-4 Inhibitor BI 1356 [(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] Increases Basal Glucagon-Like Peptide-1 and Improves Glycemic Control in Diabetic Rodent Models J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 556 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Nathan, J. B. Buse, M. B. Davidson, E. Ferrannini, R. R. Holman, R. Sherwin, and B. Zinman Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Clin. Diabetes, January 1, 2009; 27(1): 4 - 16. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Nathan, J. B. Buse, M. B. Davidson, E. Ferrannini, R. R. Holman, R. Sherwin, and B. Zinman Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Spectr, January 1, 2009; 22(1): 6 - 17. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Nathan, J. B. Buse, M. B. Davidson, E. Ferrannini, R. R. Holman, R. Sherwin, and B. Zinman Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care, January 1, 2009; 32(1): 193 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. DeFronzo, P. R. Fleck, C. A. Wilson, Q. Mekki, and on behalf of the Alogliptin Study 010 Group Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study Diabetes Care, December 1, 2008; 31(12): 2315 - 2317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Fruchart, F. M Sacks, M. P Hermans, G. Assmann, W V. Brown, R. Ceska, M J. Chapman, P. M Dodson, P. Fioretto, H. N Ginsberg, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients Diabetes and Vascular Disease Research, November 1, 2008; 5(4): 319 - 335. [Abstract] [PDF]
|
|
|
|
|
|
M. Bodmer, C. Meier, S. Krahenbuhl, S. S. Jick, and C. R. Meier Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia: A nested case-control analysis Diabetes Care, November 1, 2008; 31(11): 2086 - 2091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Selvin, S. Bolen, H.-C. Yeh, C. Wiley, L. M. Wilson, S. S. Marinopoulos, L. Feldman, J. Vassy, R. Wilson, E. B. Bass, et al. Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review Arch Intern Med, October 27, 2008; 168(19): 2070 - 2080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Aron and L. Pogach Quality indicators for diabetes mellitus in the ambulatory setting: using the Delphi method to inform performance measurement development Qual. Saf. Health Care, October 1, 2008; 17(5): 315 - 317. [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Approaches to Treatment of Type 2 Diabetes Diabetes Care, August 1, 2008; 31(8): 1697 - 1703. [Full Text] [PDF]
|
|
|
|
|
|
A. D. Rao, N. Kuhadiya, K. Reynolds, and V. A. Fonseca Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?: A meta-analysis of observational studies Diabetes Care, August 1, 2008; 31(8): 1672 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Norris, D. Kansagara, C. Bougatsos, and R. Fu Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, June 3, 2008; 148(11): 855 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Turner, J.-Y. Li, A. Gosby, S. W.C. To, Z. Cheng, H. Miyoshi, M. M. Taketo, G. J. Cooney, E. W. Kraegen, D. E. James, et al. Berberine and Its More Biologically Available Derivative, Dihydroberberine, Inhibit Mitochondrial Respiratory Complex I: A Mechanism for the Action of Berberine to Activate AMP-Activated Protein Kinase and Improve Insulin Action Diabetes, May 1, 2008; 57(5): 1414 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Cauley and K. E. Ensrud Considering Competing Risks . . . Not All Black and White Arch Intern Med, April 28, 2008; 168(8): 793 - 795. [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Nissen, S. J. Nicholls, K. Wolski, R. Nesto, S. Kupfer, A. Perez, H. Jure, R. De Larochelliere, C. S. Staniloae, K. Mavromatis, et al. Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes: The PERISCOPE Randomized Controlled Trial JAMA, April 2, 2008; 299(13): 1561 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Thomas, M. Eckhardt, E. Langkopf, M. Tadayyon, F. Himmelsbach, and M. Mark (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 175 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Grey Skeletal Toxicity of Thiazolidinediones Ann Intern Med, April 1, 2008; 148(7): 563 - 563. [Full Text] [PDF]
|
|
|
|
|
|
S. S Lund, L. Tarnow, M. Frandsen, U. M Smidt, O. Pedersen, H.-H. Parving, and A. A Vaag Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes Eur. J. Endocrinol., January 1, 2008; 158(1): 35 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Correction: Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus Ann Intern Med, December 18, 2007; 147(12): 887 - 887. [Full Text] [PDF]
|
|
|
|
|
|
Correction: "Doctor, How CERTain Are We That This Diabetes Medication Is Best for Me?" Ann Intern Med, November 20, 2007; 147(10): 743 - 743. [Full Text] [PDF]
|
|
|
|
|
|
C. D. Mulrow, J. Cornell, and A. R. Localio Rosiglitazone: A Thunderstorm from Scarce and Fragile Data Ann Intern Med, October 16, 2007; 147(8): 585 - 587. [Full Text] [PDF]
|
|
|
|
|
|
L. M. Pogach "Doctor, How Certain Are We That This Diabetes Medication Is Best for Me?" Ann Intern Med, September 18, 2007; 147(6): 428 - 430. [Full Text] [PDF]
|
|
|
|
|
|
S. Singh, Y. K. Loke, and C. D. Furberg Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis JAMA, September 12, 2007; 298(10): 1189 - 1195. [Abstract] [Full Text] [PDF]
|
|
Read all Rapid Responses
